Curza

Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology.

Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.

Curza headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $3.1B in funding across 128 round(s). With a team of 11-50 employees, Curza is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Curza, raised $5.3M. Discover more about their projects, partnerships, and impact on our platform.